Arcus Biosciences Inc. closed its IPO of 8 million common shares priced at $15 apiece to raise $138 million in gross proceeds.

The underwriters fully exercised their overallotment option to buy an additional 1.2 million shares.

Citigroup, Goldman Sachs & Co. LLC and Leerink Partners acted as joint book-running managers for the offering.